by | Jul 5, 2024 | Publications
Ann Pathol. 2024 Jul 3:S0242-6498(24)00129-9. doi: 10.1016/j.annpat.2024.06.007. Online ahead of print. ABSTRACT Multiple myeloma is a malignant plasma cell proliferation located in the bone marrow and bones. It can secondarily manifest with extraosseous involvement,...
by | Jul 5, 2024 | Publications
Sci Rep. 2024 Jul 4;14(1):15406. doi: 10.1038/s41598-024-66367-5. ABSTRACT Patients with multiple myeloma (MM) experience relapse and drug resistance; therefore, novel treatments are essential. Clotrimazole (CTZ) is a wide-spectrum antifungal drug with antitumor...
by | Jul 5, 2024 | Publications
BMC Pulm Med. 2024 Jul 4;24(1):321. doi: 10.1186/s12890-024-03129-z. ABSTRACT BACKGROUND: Patients with multiple myeloma are immunosuppressed due to both the disease itself and immunosuppressive therapies. Thus, when presenting with respiratory failure and pulmonary...
by | Jul 5, 2024 | Publications
Leuk Res. 2024 Jun 25;143:107544. doi: 10.1016/j.leukres.2024.107544. Online ahead of print. ABSTRACT Infections are major cause of morbidity and mortality in patients with multiple myeloma. Current treatment landscape of newly-diagnosed multiple myeloma includes...
by | Jul 4, 2024 | Publications
Ann Hematol. 2024 Jul 4. doi: 10.1007/s00277-024-05865-y. Online ahead of print. ABSTRACT Advances in treatment have improved the survival of multiple myeloma (MM) patients, but the disease remains incurable. Here, in this nationwide retrospective real-world evidence...
by | Jul 4, 2024 | Publications
Blood. 2024 Jul 4;144(1):124. doi: 10.1182/blood.2024025297. NO ABSTRACT PMID:38963667 | DOI:10.1182/blood.2024025297
